ArticleInflammation2012
Connexin43 modulation inhibits scarring in a rabbit eye glaucoma trabeculectomy model.
Article in Inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- From Mechanism to Therapy: Isoliquiritigenin as a Novel Anti-Inflammatory Agent for Inflammatory Disease ManagementEndocrine, metabolic & immune disorders drug targets · 2026Pooled it
- The Double-Edged Effect of Connexins and Pannexins of Glial Cells in Central and Peripheral Nervous System After Nerve Injury.Molecular neurobiology · 2025Review
- Upregulation of retinal VEGF and connexin 43 in murine nonarteritic anterior ischemic optic neuropathy induced with 577 nm laser.Experimental eye research · 2022Article
- Connexin Hemichannel Mimetic Peptide Attenuates Cortical Interneuron Loss and Perineuronal Net Disruption Following Cerebral Ischemia in Near-Term Fetal Sheep.International journal of molecular sciences · 2020Article
- Antifibrotic role of low-dose mitomycin-c-induced cellular senescence in trabeculectomy models.PloS one · 2020Article
- Morphometric analysis in mouse scleral fibroblasts using focused ion beam/scanning electron microscopy.Scientific reports · 2019Article
- Therapeutic strategies targeting connexins.Nature reviews. Drug discovery · 2018Review
- Review
- Wound Healing Modulation in Glaucoma Filtration Surgery- Conventional Practices and New Perspectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II).Journal of current glaucoma practiceReview
- Connexins and their channels in inflammation.Critical reviews in biochemistry and molecular biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated whether one subconjunctival injection of connexin43 antisense oligodeoxynucleotides (Cx43 AsODN) modulates postoperative scarring in a rabbit model of glaucoma trabeculectomy surgery. In a randomised, controlled, masked-observer study, 39 rabbits underwent trabeculectomy surgery with insertion of a 22-gauge cannula in the right eyes and were randomly divided into three treatment groups. Each rabbit received an injection of Cx43 AsODN in Pluronic gel, balanced salt solution or Pluronic gel alone into the formed bled. The animals were euthanized at 8 and 24 h and at 5 and 21 days. Histology and immunohistochemistry results demonstrated that Cx43 AsODN decreased Cx43 upregulation at 8 and 24 h which led to less myofibroblast upregulation at days 5 and 21 and reduced scarring at day 21 compared to controls. We conclude that postoperative use of Cx43 AsODN inhibited subconjunctival scarring and fibrosis. Cx43 AsODN injection may be a safe and effective anti-scarring agent in glaucoma trabeculectomy surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.